The effectiveness of cromolyn sodium versus placebo for the prophylaxis of aqthmatic symptoms was studied by using a double-blind-crossover clinical trial in 20 patients with symptomatic asthma. Eleven patients showed significant improvement in maximum voluntary ventilation, dyspnea index, and maximum mid-expiratory flow rate. Asthma uncomplicated by chronic bronchial infection predominated in this group. The average age was 32 years and the mean residual volume/total lung capacity ratio was 32 percent (SD a 10 percent). Nine patients failed to show significant improvement in the above noted variables and chronic bronchial infection was an important factor in the asthma of all these patients; the average age was 50 years and the mean residual volume/total lung capacity ratio was 54 percent (SD 5 11 percent). Good agreement between subjective assessment and objective pulmonary function measurements was noted in 18 out of 20 cases. Cromolyn sodium appears to be more effective in young asthmatics with a low incidence of bronchial infection and with only mild pulmonary hyperinflation.
romolyn sodium ( C S ) t is a new drug in the United States which has been reported to oeer a unique means of prophylaxis in asthma. The drug has been evaluated in numerous single and doubleblind studies in England, Fi'estern Europe, Japan, Australia, Canada and Israel, as well as the United States.'-" Reports of its efficacy as well as its indications in asthma have varied. Considering these several clinical and experimental results, we designed a double-blind-crossover clinical study of CS which would measure pulmonary function more extensively than in prior studies and hopefully determine which of these tests would be most useful in objectively assessing the clinical course of patients on CS therapy.
The mechanism of action of CS is unlike any previously used mode of therapy. CS is a chromone derivative with an unusual characteristic in that it has been found to specifically inhibit the release of OFrom figure. 7
The activt. agent used in this study consisted of capsr~les containing cromolyn sodii~m 20 mg and lactose ab: dilnent. Identically appearing placebo capsr~les mntaining anhydrous sodir~m sulfate 5 mg and lactose dilr~ent were used. The sodium sulfate mimics the bitter taate of the active d n~g .
The capsi~les were ad~ninistered by inhalation four times per day via the Spinhaler.Ll4 It was found that the patients coctld he taught to use this appliance and that a trial period using placebo for practice was unnecessary.
A douhle-l>lind-crossover technique of evaluation was used, each patient receiving CS or placebo for one month followed by a one week "no d n~g " periocl (to avoid pnssible carry-over) and then one month on the agent not nsecl in the first month. Order of administration was randomized; physicians and patients were unaware of which agent wi~s lwing Clinical Xlaterial Twenty-four patients were selected from the clinics of the University of Nebraska Regional Chest Center and from the private practice of an allergist affiliated with the University Sledical Center. Selection was made from patients with the tliagnosis of severe allergic asthma who had airways denionstrahly respmsive to bronchodilators and spr~tu~n eosinophilia. The patients ranged in age from 13 to 66 years and duration of illness ranged from 4 to 40 years. Those receiving tlesensitization and/or steroid therapy were asked to maintain the current level of therapy throughout the sh~dy. BronchodiIntors and antibiotics were permitted on a PRN basis. Four patients were lost to clinical follow-up due to p w r cooperation.
Each patient received a complete initial workup consisting of history and physical exaniination, allergy skin testing, complete I>I(n)d count including absolute eosinophil count, l>lood chernistry ( senlrn transaniinase, alkaline phosphatase and I>lood urea nitrogen), nrinalysis, spuh~m eosinophils, clectn)cardiogra~n, chest roentgenograms (inclr~ding ~nidco-ronal planigra~n ) and baseline pulmonary function testing. The latter inclutled: meast~rements of vital capacity (VC), total lung capacity ( T L C ) by the bcdy plethysniograph techniq~te,lh forced expiratory volunle in the first second the difference between total lung capacity ;~ntl vital citpacity. Oxygen consumption was also obtained at rest, tlr~ring trn minutes of exercise and after c o~n~l e t t * rcbcovcrv. Clinical improvement was t.valt~att.d objectively 1)y reptbic.ating blotwl cor~nts and chemistry, r~rinalysis, electrc~ardiogra~~l, VC, FEVI, SIVV, SlSlFR, dyspnea intlex ant1 oxygtbn consrnnption sh~dies at the end of each tnontlily course of therapy.
Sr~bjective assessnient was acco~nplislietl I>y taacl1 patient BURGHER, ELLIOTT AND KASS using daily score cards. Wheezing, dyspnea, tightness, cough and sputum production were graded twice daily on a one to ten scale. Use of other medications including antibiotics was also recorcled. In like manner, attending physicians recorded the same variables biweekly. At the conclusion of the double-blind study the patient selected which agent he or she felt better on and the physicians selected the period of best clinical control of syn~ptoms. The d n~g "code" was then broken and a comparison of placebo versus active agent was made for all tests by statistical analysis, finding "t" for the difference between correlated pairs of observations and using a probability of 0.05 as the level of statistical s i g n i f i c a n c e .~~a t i n g s by patients and physician were evaluated hy the Wilcoson Slatchecl-Pairs Signed-Ranks test. In this test "t" must be eclr~al to or less than 31 in order to be significant at the 0.005 level for the one-tailed test or a t the 0.01 level for the two-tailed test."
Subjective Evaluations
For the patient's own ratings of active versus placebo, the difference did not quite reach statistical significance at the level stated above (T-34). However, the rating by the physicians was significant at the 0.005 level (T-20.5) in favor of the active agent. A close examination of the data reveals some justification for this apparent paradox. In two instances patients who were having marked wheezing and dyspnea initially were randomly started on the active agent. Their relief was such that they ranked their initial symptoms as "zero" and continued to do so throughout the course of study. Conversely, the same patients when ranked more critically by physicians had symptom scores as high as five on a ten point scale. This represents an inadequate rating by these two patients which had an obvious effect on results. In 18 out of 20 instances the physician and patient were in agreement subjectively as to the period of most relief and in each case this period was while on CS.
Pulmonary Function Studies
In 12 cases the amount of oxygen consumed during the exercise was less on the active drug, but was not statistically significant (P>0.05). No statistically significant changes were noted in VC or FEV, ( P > 0.05). MVV showed a significant increase on active drug ( P < 0.05) while MMFR approached statistical significance ( P between 0.05 and 0.10). The dyspnea index was improved in 14 patients while on active drug but not at a significant level ( P < 0.05 ).
Based on clinical response the patients were divided into two groups. Group A (11 patients) showed significant increase in h l W ( P < 0.01 ), of 111IFR ( P < 0.05) and a significant decrease of dyspnea index ( P < 0.05). Their average age was 32 years and the mean residual volume/total lung capacity ratio was 32 percent with a standard deviation of 10 percent. Group B (nine patients) showed a nonsignificant change of MVV, MMFR and dypsnea index ( P > 0.20). Their average age was 50 years and the mean RV/TLC ratio was 54 percent with a standard deviation of i-11 percent. All patients in Group B and only one patient in Group A suffered from chronic bronchial infection.
Toxicity
No evidence of toxicity was elicited from examination of blood count and chemistry or urinalyses. The electrocardiograms and chest roentgenograms remained unchanged throughout the study. Seven patients noted an initial transient throat irritation when on both active and placebo agents, but seemed to adapt to both agents in three to four days after initiation of therapy.
The clinical evaluation of asthma and its response to therapy is elusive and complex, a fact universally accepted by clinicians. This is attributed to the nature of the disease process, its varied etiologies, and the patient's own problem of interpreting the severity of his condition. The design of the present study was such that both objective physiologic testing and subjective impressions by the patient and physician were assessed. It seems significant that in 18 out of 20 cases both patient and physician selected CS as the agent which offered the most relief and freedom from symptoms. These 18 patients also felt the drug had carried them through their most difficult season of the year with less impairment than in comparable periods in the past.
Since it is not readily apparent from the data, a brief comment emphasizing the marked clinical improvement in two patients seems necessary. Both were life-long asthmatics in their mid-twenties. They were inclined toward athletic sports, but were severely restricted in all activities, even to the point of one of them not being able to shower. After being continued on CS therapy for ten months following completion of the double-blind trial both patients have complete absence of symptoms of asthma, and have been performing numerous physical activities which were heretofore impossible.
One patient was later found to have a significantly lowered level of serum alphal antitrypsin. This correlated with her marked pulmonary hyperinflation. As would be expected she did not improve with CS, although it seems quite likely that she did Our intent in this study was to investigate available techniques for testing response of the asthmatic airway to this drug. However, it soon became evident that some of the more elaborate and expensive methods of measuring pulmonary function were less useful than frequent monitoring of simple mechanics of breathing ( MVV, MMFR, dyspnea index). Improvement of the latter variables corresponded well with physician-patient assessment in distinguishing the placebo from CS in those patients showing CS response. Patients who demonstrated improvement were younger, had only minimal lung hyperinflation and were free of bronchial infection compared with those failing to improve who were older, had moderate to severe lung hyperinflation and all had frequent bronchial infections.
An excellent index of response evolved in this study which should aid the clinician in determining if this drug is indicated in a given patient. The ratio of residual volume to total lung capacity ( RV/ TLC ) provides good evidence of pulmonary hyperinflation and is an excellent yardstick for predicting CS response in the allergic asthmatic. It is our feeling that a patient with a RV/TLC ratio greater than 40 percent is less likely to derive adequate benefit from CS. For this reason the drug offers great hope for the young asthmatic who has not yet sustained damage. An obvious implic a t' ion of this is the possibility of delaying or even preventing lung damage as the patient becomes older and continues therapy.
